3 things to know:
1. An evaluation of Sycamore after three months saw pain reduction of about 65 percent according to the pain scales Owestry Disability Index and Visual Analog Scale, according to a Dec. 20 news release.
2. A previous study showed a 40 percent increase in compressive strength between a vertebra instrumented with the Sycamore device and a vertebra that had undergone only a simple balloon kyphoplasty.
3. Safe Orthopaedics expects to launch Sycamore outside the U.S. in January. The company expects FDA approval in the second half of 2022.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
